Navigation Links
PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
Date:9/9/2011

OXFORD, England, September 9, 2011 /PRNewswire/ --

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

Dr Fintan Walton, CEO, PharmaVentures commented, "We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders.  With 20 years' experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site."

The facility is part of the recent integration of Astex Therapeutics Limited and SuperGen Inc. and provides an opportunity to build out a fully integrated CMC capability in a prime but low cost West Coast US location.  The site's team has significant experience in preclinical as well as Phase I, II and III drug product development as evidenced by over 30 patents and the successful oversight of a number of global regulatory filings.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals.  The transactions team has an established track record in generating outstanding value for PharmaVentures' clients and has assisted in over 100 transactions in the past 20 years.  

For enquiries regarding this opportunity or how we can help your company to achieve its business goals, please contact:

Dr Jansen Jacobs
Senior Advisor
PharmaVentures Ltd
jansen.jacobs@pharmaventures.com
+44-7951-205420


'/>"/>
SOURCE Pharma Ventures Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
8. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
9. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... and EMERYVILLE, Calif., May 14 Bayer HealthCare Pharmaceuticals, ... ) today announced that more than 65 studies evaluating ... at the 2009 American Society of Clinical Oncology (ASCO) ... cancers - in the treatment of unresectable hepatocellular carcinoma ...
... and Phase 1 safety studies, and plans for Phase ... (BPH) are to be presentedCINCINNATI, May 14 Ausio ... for an aging global population, will lead off the ... 2009 at 9:00 AM in Atlanta, Georgia. Ausio has ...
... Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular and metabolic disease, today ... 2 clinical trial of its lead drug, VIA-2291 in ...
Cached Biology Technology:Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 2Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 3Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 4Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 5Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 6Ausio Pharmaceuticals to Present at Bio(R) 2009 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:4/23/2014)... 2 million Food Standards Agency (FSA) project to map ... workers. , Norovirus outbreaks can rapidly affect large ... frozen strawberries infected 11,000 people in Germany, but there ... strains cause infection and which foods are the most ... will produce data that will help the FSA to ...
(Date:4/22/2014)... will lead a five-year, $3 million study to determine ... the transport of dissolved organic matter (DOM) through the ... the chemical composition and water quality of the watershed ... National Science Foundation,s MacroSystems Biology program, researchers will collect ... begins in Canada and runs through five U.S. states, ...
(Date:4/22/2014)... Calif. Inspired by the fist-like club of ... University of California, Riverside, in collaboration with University of ... structure for composite materials that is more impact resistant ... "The more we study the club of this tiny ... so many things we use every day," said David ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... the body of pathogens. As important as resisting infection, is ... toxins produced by pathogens or by components of the host ... damage inflicted to different tissues and organs that, if uncontrolled, ... , The in-built capacity that an infected individual has ...
... LANSING, Mich. In the current issue of Science ... virus evolves, which sheds light on how easy it can ... showed for the first time how the virus called "Lambda" ... an innovation that took four mutations to accomplish. This virus ...
... magician employing sleight of hand, the protein mitoNEET -- a ... draws the eye with a flurry of movement in one ... else. Using a combination of laboratory experiments and computer ... San Diego (UCSD) have deciphered part of mitoNEET,s movements to ...
Cached Biology News:European Research Council supports search for regulators of tissue damage 2MSU researchers show how new viruses evolve, and in some cases, become deadly 2Rice, UCSD scientists probe form, function of mysterious protein 2Rice, UCSD scientists probe form, function of mysterious protein 3
... assay kit designed to detect poly(ADP-ribose) polymerase ... an enzyme implicated in DNA damage and ... by caspase-3. Cleavage of PARP from the ... a hallmark of apoptosis. Each kit is ...
... comes with a shutter (controlled via a TTL ... The DH-2000 Deuterium Tungsten Halogen Light ... tungsten halogen light sources in a single optical ... stable output from 215-200 nm. In addition, deep-UV ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... Nematode microRNA Microarray contains all known ...
Biology Products: